We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
    • eCFR and Guidances
    • White Papers
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Warns Hand Biomechanics Over MDR, GMP Issues

FDA Warns Hand Biomechanics Over MDR, GMP Issues

January 5, 2018

Hand Biomechanics Lab, a manufacturer of bone fixation fastener systems in Sacramento, California, was hit with an FDA warning letter for failing to submit MDRs and for GMP nonconformities.

The firm’s procedure for MDR submissions lacked definitions for terms such as “become aware,” “caused or contributed,” and “MDR reportable event” that may have caused it to make inappropriate decisions when evaluating complaints. It was also flagged for incomplete investigations and for not providing timely MDR submissions.

The firm failed to submit MDRs after it received at least three complaints regarding patients who required prescription antibiotics for pin site infections developed while being treated with the Digit Widget device, and another complaint about a patient having the device surgically removed due to the infection sustained with use.

The firm did not submit MDRs to the agency for these complaints and others, according to the warning letter, even though they describe events in which “medical intervention was necessitated to preclude permanent impairment of a body function or permanent damage to a body structure.”

The GMP nonconformities that resulted in adulterated devices relate to failing to demonstrate the sealing process could produce “repeatable and reproducible seals capable of maintaining seal integrity throughout the shelf-life of the product” and evaluating defects.

In addition, at least 10 CAPA records between Feb. 24, 2015 and Feb. 3, 2017 lacked investigations, corrective actions or preventive actions, the FDA said.

Devices Inspections and Audits Regulatory Affairs QSR

Upcoming Events

  • 06Jun

    Gene & Cell Therapy Regulation: Comparability and Other New Developments

  • 07Jun

    Developing World-Class SOPs: Optimizing Quality and Compliance

  • 08Jun

    Implementing ICH E8 R1 Recommendations Increases Site and Participant Relationship Scoring Measures

  • 13Jun

    Winners Only: 3 Steps to Compete in Digital Quality

  • 14Jun

    Pharmaceutical Quality Risk Management and ICH Q9(R1): Navigating the Global Intersection of Principle and Regulation

  • 20Jun

    What’s CSA? And how can it streamline your GxP System Verification?

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • FDA Approves Pfizer Abrysvo RSV Vaccine for Older Adults

  • GE HealthCare Sees Clearance of Precision DL System to Enhance Scan Image Quality

  • FDA Approves Lynparza Combination for Certain Metastatic Prostate Cancer

  • Ezra Sees 510(k) Clearance for Ezra Flash AI Product for Faster, Better MRI Images

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing